Boundless Bio, Inc. (BOLD) Stock

Boundless Bio, Inc. (BOLD) is a Healthcare stock trading at $3.00 (as of 2026-08-21), with a market capitalization of $68.24M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Boundless Bio, Inc. is a clinical-stage oncology company developing cancer therapeutics that target extrachromosomal DNA. Its pipeline includes BBI-355 (an oral checkpoint kinase 1 inhibitor) for oncogene-amplified cancers and BBI-825 (an oral ribonucleotide reductase inhibitor) for resistance gene amplifications, along with an ecDTx 3 program in early development.

Understand Boundless Bio, Inc.: how it makes money

Boundless Bio develops oral oncology therapeutics (including its lead candidate BBI-355) aimed at oncogene amplified tumors and other genetic drivers, and it is currently generating 0.0B revenue in its latest reported period.

The profit model is dominated by whether its pipeline oncology candidates (BBI-355 and BBI-825) progress from Phase 1/2 into successful outcomes that can later translate into commercial revenue, since the latest reported period shows no revenue.

Business quality (Weak): High-level business and pipeline details are clear, but there are no provided reportable segments or operating KPI definitions in the inputs, limiting what an investor can track quarter to quarter beyond the clinical-stage narrative and current loss profile.

Bull case

  • Pipeline focus on specific tumor genetics: BBI-355 targets extrachromosomal DNA in oncogene amplified tumors and is an oral inhibitor of checkpoint kinase 1 (in Phase 1/2).
  • Multiple clinical-stage candidates: BBI-825, an oral inhibitor of ribonucleotide reductase, is in Phase 1/2 for cancer patients with resistance gene amplifications.

Bear case

  • Clinical-stage execution risk: Both BBI-355 and BBI-825 are in Phase 1/2, so outcomes that lead to approval and eventual revenue are uncertain.
  • No current revenue and large operating losses: In the latest reported period ended 2026-03-31, revenue is 0.0B and operating margin is -1573.4, consistent with a business that has not yet commercialized products.
Valuation — source: SEC EDGAR (first-party)
Price$3.00
Market Cap$68.24M
Price / Book1.03
Price / Sales17.96
FCF Yield-150.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$5.36M
Net Margin-1086.4%
Revenue Growth (YoY)-32.1%
EPS Growth (YoY)-32.5%
FCF Growth (YoY)-25.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.18 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($8.74M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOZachary Hornby
Employees64
CountryUS
IPO Date2016-07-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Rein Therapeutics Inc. (RNTX)
  • Spero Therapeutics, Inc. (SPRO)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • XBiotech Inc. (XBIT)
  • OS Therapies Incorporated (OSTX)
  • MediciNova, Inc. (MNOV)
  • Cypherpunk Technologies Inc. (CYPH)
  • Lixte Biotechnology Holdings, Inc. (LIXT)
BOLD earnings history · BOLD institutional & insider holders · BOLD KPIs & operating metrics · BOLD financials · BOLD investor presentations & press releases · BOLD SEC filings · BOLD peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.